U.S. markets open in 8 hours 21 minutes
  • S&P Futures

    3,632.25
    -0.50 (-0.01%)
     
  • Dow Futures

    29,973.00
    -25.00 (-0.08%)
     
  • Nasdaq Futures

    12,106.25
    +30.25 (+0.25%)
     
  • Russell 2000 Futures

    1,851.10
    -0.40 (-0.02%)
     
  • Crude Oil

    45.08
    +0.17 (+0.38%)
     
  • Gold

    1,801.10
    -3.50 (-0.19%)
     
  • Silver

    23.16
    -0.14 (-0.62%)
     
  • EUR/USD

    1.1905
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    0.8820
    0.0000 (0.00%)
     
  • Vix

    21.64
    -1.02 (-4.50%)
     
  • GBP/USD

    1.3348
    -0.0010 (-0.08%)
     
  • USD/JPY

    104.4790
    -0.0010 (-0.00%)
     
  • BTC-USD

    18,849.34
    -219.15 (-1.15%)
     
  • CMC Crypto 200

    373.69
    +3.94 (+1.07%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,372.55
    +206.96 (+0.79%)
     

ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference

·1 min read

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual London Healthcare Conference. The presentation is scheduled for November 18, 2020 at 12:00pm ET.

A webcast of the presentation will be accessible through the Investors and Media section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201104005579/en/

Contacts

INVESTOR RELATIONS AND MEDIA
ImmunoGen
Courtney O’Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com